By Katherine Hamilton
Becton Dickinson and Co. said it plans to break off its bioscience and diagnostic solutions business to focus on medical technology.
Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and allow the company to invest more in innovation and margin growth.
The separation is scheduled to be completed in 2026, the company said.
After the separation, BD expects to have $17.8 billion in fiscal 2024 revenue. The biosciences and diagnostics business is expected to make $3.4 billion in revenue for that year.
BD expects to invest in research and development and capital allocation including mergers and acquisitions. Investments will focus on its businesses in medical manufacturing, medication management, biopharmaceuticals and chronic condition treatments.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
February 05, 2025 16:54 ET (21:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。